JP6224615B2 - 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 - Google Patents

抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 Download PDF

Info

Publication number
JP6224615B2
JP6224615B2 JP2014549212A JP2014549212A JP6224615B2 JP 6224615 B2 JP6224615 B2 JP 6224615B2 JP 2014549212 A JP2014549212 A JP 2014549212A JP 2014549212 A JP2014549212 A JP 2014549212A JP 6224615 B2 JP6224615 B2 JP 6224615B2
Authority
JP
Japan
Prior art keywords
angiogenesis
administration
cancer
treatment
vlo4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014549212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506352A5 (enExample
JP2015506352A (ja
Inventor
フェン，シャオドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Northstate College of Pharmacy LLC
Original Assignee
California Northstate College of Pharmacy LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Northstate College of Pharmacy LLC filed Critical California Northstate College of Pharmacy LLC
Publication of JP2015506352A publication Critical patent/JP2015506352A/ja
Publication of JP2015506352A5 publication Critical patent/JP2015506352A5/ja
Application granted granted Critical
Publication of JP6224615B2 publication Critical patent/JP6224615B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014549212A 2011-12-22 2012-12-18 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 Active JP6224615B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/374,369 US8946159B2 (en) 2011-12-22 2011-12-22 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
US13/374,369 2011-12-22
PCT/US2012/070399 WO2013096335A1 (en) 2011-12-22 2012-12-18 Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment

Publications (3)

Publication Number Publication Date
JP2015506352A JP2015506352A (ja) 2015-03-02
JP2015506352A5 JP2015506352A5 (enExample) 2016-05-19
JP6224615B2 true JP6224615B2 (ja) 2017-11-01

Family

ID=48655153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549212A Active JP6224615B2 (ja) 2011-12-22 2012-12-18 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与

Country Status (5)

Country Link
US (6) US8946159B2 (enExample)
EP (2) EP2793924B1 (enExample)
JP (1) JP6224615B2 (enExample)
CN (1) CN104159596B (enExample)
WO (1) WO2013096335A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
TWI579299B (zh) * 2014-08-22 2017-04-21 國立成功大學 去整合蛋白變異體及其醫藥用途
US11597727B2 (en) 2018-03-13 2023-03-07 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
EP4142707A4 (en) 2020-05-01 2024-09-18 The Regents of the University of California ALPHA-2-BETA-1 INTEGRIN INHIBITORS AND METHODS OF USE THEREOF
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019088A1 (en) 1992-03-17 1993-09-30 Board Of Regents, The University Of Texas System Neurotrophic peptides
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
DE60127656T2 (de) * 2000-02-25 2007-12-20 Immunex Corp., Seattle Integrin antagonisten
US20040121031A1 (en) 2002-12-09 2004-06-24 Muhammed Majeed Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin
US7101707B2 (en) 2002-12-23 2006-09-05 Cedars-Sinai Medical Center Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances
CN1933851B (zh) * 2004-03-24 2011-09-14 艾伯特生物治疗学公司 使用抗-α5β1抗体抑制癌细胞增殖
JP4857259B2 (ja) 2004-03-24 2012-01-18 アボット バイオセラピューティクス コーポレイション 癌細胞増殖を阻害するための抗α５β１抗体の使用
CA2611319A1 (en) * 2005-06-07 2006-12-14 William F. Degrado Inhibitors of the .alpha.2.beta.1/gpia-iia integrin
EP1984391A4 (en) 2006-01-19 2009-08-12 Eyegene Inc PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM
EP1998759A2 (en) 2006-03-23 2008-12-10 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
US20080267978A1 (en) 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
WO2009114776A2 (en) 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
US20100105644A1 (en) 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
WO2010070675A2 (en) 2008-12-01 2010-06-24 Laila Pharmaceuticals Pvt. Ltd Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2011146842A1 (en) 2010-05-20 2011-11-24 Temple University - Of The Commonwealth System Of Higher Education Process for synthesis of silane dipeptide analogs
US20110311335A1 (en) * 2010-06-21 2011-12-22 Douglas Wike Removable fastener
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
IL210587A0 (en) 2011-01-12 2011-03-31 Adel Jamil Hidmi Natural preparation for treatment of skin sores and lesions
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment

Also Published As

Publication number Publication date
US20220226431A1 (en) 2022-07-21
US20240342240A1 (en) 2024-10-17
EP3777877A1 (en) 2021-02-17
US11318184B2 (en) 2022-05-03
US12053504B2 (en) 2024-08-06
US20200397856A1 (en) 2020-12-24
EP2793924A1 (en) 2014-10-29
US20130225495A1 (en) 2013-08-29
HK1203391A1 (en) 2015-10-30
WO2013096335A8 (en) 2014-03-27
CN104159596B (zh) 2017-03-08
JP2015506352A (ja) 2015-03-02
WO2013096335A1 (en) 2013-06-27
US8946159B2 (en) 2015-02-03
EP2793924B1 (en) 2020-11-04
US10722555B2 (en) 2020-07-28
CN104159596A (zh) 2014-11-19
EP3777877B1 (en) 2024-08-07
US20130165380A1 (en) 2013-06-27
EP2793924A4 (en) 2015-08-26
US8815805B2 (en) 2014-08-26
US20150105320A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
US12053504B2 (en) Anti-angiogenic treatment using VLO4 with a blocking peptide
Wang et al. Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
Xiong et al. Integrins regulate stemness in solid tumor: an emerging therapeutic target
US20240390458A1 (en) Treatment system for synergistically inhibiting a sprout angiogenesis
Cianfrocca et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
US20230021383A1 (en) Spatiotemporal delivery system embedded in 3d-printing
EP3154586B1 (en) Treating lymphomas
US10925852B2 (en) Talc-bound compositions and uses thereof
RS57524B1 (sr) Anti-alfa-v integrin antitelo za tretman kancera prostate
Syrigos et al. Adhesion molecules as targets for the treatment of neoplastic diseases
HK1203391B (en) Administration of an antagonist of alpha 5 beta1 for anti-antiogenesis and cancer treatment
US8080252B2 (en) Compounds and methods of modulating angiogenesis
Kwakwa Targeting Gli-Mediated Transcription in Bone Metastasis: An Emerging Therapeutic Approach for Patients with Tumor-Induced Bone Disease
Swenson et al. Anti-Angiogenesis and disintegrins
Kashba Cerebral arteriovenous malformations: Radiosurgery-enhanced molecular targeting therapy
Gordon et al. Jacobs Journal of Internal Medicine
Alavi et al. Chaper 6
HK1234674A1 (en) Treating lymphomas
HK1234674B (en) Treating lymphomas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171005

R150 Certificate of patent or registration of utility model

Ref document number: 6224615

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250